Safety and Efficacy of SMART101 in Adult Patients With Hematological Malignancies After Haploidentical HSCT With Post-transplant Cyclophosphamide

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 6, 2023

Primary Completion Date

July 31, 2025

Study Completion Date

July 31, 2026

Conditions

Hematological Malignancies

Interventions

BIOLOGICAL

Allogeneic T cell progenitors, cultured ex-vivo

Injection of T cell progenitors 6 days after haplo HSCT and 2 days after the last administration of cyclophosphamide

Trial Locations (4)

RECRUITING

Institut Paoli Calmettes, Marseille

RECRUITING

CHU Toulouse- Institut Universitaire du cancer Toulouse- Oncopole, Toulouse

RECRUITING

Centre hospitalier universitaire de Nantes, Nantes

RECRUITING

Hôpital Saint-Louis, Paris

All Listed Sponsors

lead

Smart Immune SAS

INDUSTRY